Mezatil Sr

Diltiazem, the active ingredient in Mezatil Sr, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to treat hypertension, angina pectoris and to control ventricular rate in atrial fibrillation, primarily in adult patients.\n\nGNH India supplies Mezatil Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diltiazem is a calcium channel blocker used to manage cardiovascular conditions.\n\nHypertension: lowers elevated blood pressure by relaxing vascular smooth muscle.\nAngina pectoris: reduces myocardial oxygen demand and improves coronary blood flow.\nChronic stable angina: alleviates chest pain during exertion by decreasing cardiac workload.\nAtrial fibrillation rate control: slows atrioventricular nodal conduction to maintain an appropriate ventricular rate.

Adverse reactions may vary in frequency and severity.\n\nCommon Side Effects:\n- Headache\n- Flushing\n- Peripheral edema\n- Dizziness\n\nSerious or Rare Side Effects:\n- Severe bradycardia or heart block\n- Marked hypotension\n- Hepatic dysfunction\n- Allergic reactions such as rash or angioedema\n- Myocardial infarction

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.\n\nMonitor blood pressure: ensure adequate control without excessive hypotension.\nAssess cardiac function: watch for bradyarrhythmias, especially in patients with pre‑existing conduction disorders.\nUse caution in hepatic impairment: dose adjustment may be required.\nAvoid abrupt discontinuation: taper to prevent rebound hypertension.\nAdjust dose in renal impairment: consider renal function when dosing.\nStore at room temperature: keep in the original container, protect from moisture and direct sunlight.

Diltiazem can interact with several medicines, altering its efficacy or safety.\n\nMajor Interactions (Avoid):\n- Beta‑blockers: additive bradycardia and AV‑node block.\n- Digoxin: increased serum digoxin levels, risk of toxicity.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): elevated diltiazem concentrations.\n- Other antihypertensives: additive hypotensive effect.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced diltiazem exposure.\n- Diuretics: electrolyte shifts may enhance hypotensive response.\n- NSAIDs: may diminish antihypertensive efficacy.